Neoadjuvant Abiraterone Helps Clear Aggressive, Early Stage Prostate Tumors
May 16, 2012|Hematology and Oncology
Author and Disclosure Information
FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
In related news, the European National Institute for Health and Clinical Excellence just gave abiraterone the nod for late-stage cancer patients in England and Wales, after initially rejecting the drug for not being cost effective at roughly £3,000 a month.
Cougar Biotechnology sponsored the trial. Dr. Taplin reported consulting or advising for and honoraria and research funding from Johnson & Johnson, which markets abiraterone through Janssen Pharmaceuticals. Her coauthors reported financial relationships with several firms including employment and stock ownership with Johnson & Johnson.
